MedCity News October 17, 2025
Drugs selected for the FDA’s new Commissioner’s National Priority Review Voucher pilot program could receive a regulatory decision in two months or less. Qualifying product candidates must address a national priority, such as filling an unmet medical need or boosting domestic drug manufacturing.
A gene therapy for hearing loss. A drug that helps people quit e-cigarettes or vaping. An anesthetic whose main ingredient will be manufactured in the U.S. These are among the first nine therapies selected by the FDA for a new program that will accelerate regulatory review of products that meet certain national interest goals.
Each product selected for this program was awarded what’s called a Commissioner’s National Priority Review Voucher (CNPV). Standard drug review is 10 to...
Today's Sponsors
Today's Sponsor